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Retinoid X receptor-alpha (RXRa), an intriguing and
unique drug target, can serve as an intracellular
target mediating the anticancer effects of certain
nonsteroidal anti-inflammatory drugs (NSAIDs),
including sulindac.We report the synthesis and char-
acterization of two sulindac analogs, K-8008 and
K-8012, which exert improved anticancer activities
over sulindac in a RXRa-dependent manner. The an-
alogs inhibit the interaction of the N-terminally trun-
cated RXRa (tRXRa) with the p85a subunit of PI3K,
leading to suppression of AKT activation and induc-
tion of apoptosis. Crystal structures of the RXRa
ligand-binding domain (LBD) with K-8008 or K-8012
reveal that both compounds bind to tetrameric
RXRa LBD at a site different from the classical
ligand-binding pocket. Thus, these results identify
K-8008 and K-8012 as tRXRamodulators and define
a binding mechanism for regulating the nongenomic
action of tRXRa.
INTRODUCTION
Retinoid X receptor alpha (RXRa), a unique member of the nu-
clear receptor superfamily, regulates a broad spectrum of phys-
iological functions including cell differentiation, growth, and
apoptosis (Germain et al., 2006; Szanto et al., 2004). Like other
nuclear receptors, RXRa acts as a ligand-dependent transcrip-
tion factor (Germain et al., 2006; Szanto et al., 2004). Recent
accumulating evidence indicates that RXRa also has extranu-
clear actions. RXRa resides in the cytoplasm at certain stages
during development (Dufour and Kim, 1999; Fukunaka et al.,
2001) and migrates from the nucleus to the cytoplasm in
response to differentiation, apoptosis, and inflammation (Cao
et al., 2004; Casas et al., 2003; Zimmerman et al., 2006). RXRa
exhibits a modular organization structurally consisting of three
main functional domains: an N-terminal region, a DNA-binding596 Chemistry & Biology 21, 596–607, May 22, 2014 ª2014 Elsevierdomain, and a ligand-binding domain (LBD). The LBD possesses
a ligand-binding pocket (LBP) for the binding of small mole-
cule ligands, a transactivation function domain termed AF-2
composed of helix 12 (H12) of the LBD, a coregulator binding sur-
face, and a dimerization surface (Germain et al., 2006; Szanto
et al., 2004). The ligand-dependent transcription regulation is
predominately mediated through H12 that is highly mobile.
Agonist ligand binds to the LBPand helpsH12 to adopt the active
conformation that forms a surface to facilitate the binding of co-
activators and subsequent transactivation. In contrast, in the
absence of an agonist ligand or in the presence of an antagonist
ligand, H12 adopts an inactive conformation that favors the bind-
ing of corepressors to inhibit target gene transcription. Natural
RXRa ligand 9-cis-retinoic acid (9-cis-RA) and synthetic ligands
have been effective in preventing tumorigenesis in animals, and
RXRa has been a drug target for therapeutic applications, espe-
cially in the treatment of cancer (Bushue andWan, 2010; Yen and
Lamph, 2006). Targretin, a synthetic RXR-selective retinoid (rexi-
noid), was approved for treating cutaneous T-cell lymphoma
(Dawson and Zhang, 2002). RXRa can bind to DNA and activate
transcription of target genes either as a homodimer or a hetero-
dimer with its heterodimerization partners including retinoic acid
receptor, vitamin D receptor (VDR), thyroid hormone receptor
(TR), and peroxisome-proliferator-activated receptor (Germain
et al., 2006; Szanto et al., 2004). In addition to homodimer and
heterodimer, RXRa could also self-associate into homotetramers
in solution, which rapidly dissociate into active dimers upon
binding of a cognate ligand (Chen et al., 1998; Kersten et al.,
1995). Tetramer formation of RXRa might serve to sequester
the receptor’s active species, dimers andmonomers, into a tran-
scriptionally inactive tetramer complex (Gampe et al., 2000).
Effortsondiscoveryof smallmolecules targetingRXRa for ther-
apeutic application have been primarily focused on the optimiza-
tion of the molecules that bind to its classical LBP (de Lera et al.,
2007; Germain et al., 2006; Szanto et al., 2004). However, various
studies have recently identified small-moleculemodulators of nu-
clear receptors that function via unknown sites and undefined
mechanisms of action (Buzo´n et al., 2012; Moore et al., 2010).
The recent report of the structure of estrogen receptor-b (ERb)
with a secondmolecule of 4-hydroxytamoxifen bound in its coac-
tivator-binding surface represents a direct example of a secondLtd All rights reserved
Figure 1. Chemical Structures and Synthesis
(A) The structures of sulindac and its analogs
K-80003, K-8008, and K-8012.
(B) Synthesis scheme of K-8008 and K-8012.
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the possible pharmacological effects of the drug (Wang et al.,
2006). Compounds that bind to the surface binding sites of LBD
have been demonstrated for other nuclear receptors, including
androgen receptor (AR), VDR, and TR (Buzo´n et al., 2012; Moore
et al., 2010). However, compounds that bind to RXRa at the sites
other than the classical LBP have not been reported.
We recently showed that certain nonsteroidal anti-inflamma-
tory drugs (NSAIDs), including etodolac (Kolluri et al., 2005)
and sulindac (Zhou et al., 2010), could bind to RXRa and modu-
late its biological activities. Interestingly, sulindac but not 9-cis-
RA could inhibit the binding of an N-terminally truncated RXRa
protein (tRXRa) to the p85a regulatory subunit of phosphatidyli-
nositol-3-OH kinase (PI3K), leading to inhibition of the tumor ne-
crosis factor-a (TNF-a)-activated PI3K/protein kinase B (AKT)
pathway (Zhou et al., 2010). We also demonstrated, through a
designed sulindac analog, K-80003, the feasibility of developing
a new generation of RXRa-specific molecules for therapeutic
application and mechanistic studies of RXRa (Wang et al.,
2013; Zhou et al., 2010). These results identify sulindac and
related analogs as unique regulators of tRXRa activity through
an undefined binding mechanism. Here we report our synthesis
and characterization of K-80003-based analogs, K-8008 and
K-8012, which exhibited improved activity in inhibiting the
tRXRa-mediated PI3K/AKT signaling pathway. Moreover, ourChemistry & Biology 21, 596–607, May 22, 2014X-ray crystallographic studies of the LBD
of RXRa in complex with K-8008 or K-
8012 revealed that both compounds
bound to the RXRa LBD in its tetrameric
form via a particular site outside of the
classical RXRa LBP, providing a different
strategy for developing RXRa-based
agents for cancer therapy.
RESULTS
K-8008 and K-8012 Are Antagonists
of RXRa
In an effort to identify improved sulindac
analogs for cancer therapy, we designed
and synthesized a series of analogs
around K-80003 (Wang et al., 2013;
Zhou et al., 2010). The analogs shown in
Figure 1 were initially evaluated by the
reporter assay using a chloramphenicol
acetyltransferase (CAT) reporter contain-
ing TREpal that is known to bind to
RXRa homodimer (Zhang et al., 1992).
9-cis-RA strongly induced the TREpal
reporter activity, which was inhibited by
BI-1003, a known RXRa antagonist (Lu
et al., 2009). K-8008 and K-8012 also ex-hibited an inhibitory effect on 9-cis-RA-induced TREpal reporter
activity in a concentration-dependent manner (Figure 2A),
although they did not show any agonist activity at the concentra-
tions used (Figure 2B). The antagonist effect of K-8008 and
K-8012 was much better than sulindac and comparable to
K-80003 (Figure 2A). We also used the Gal4-RXRa-LBD chimera
and Gal4 reporter system to evaluate the inhibitory effect of
K-8008 and K-8012 on 9-cis-RA-induced reporter activity.
Cotransfection of Gal4-RXRa-LBD strongly activated the Gal4
reporter in the presence of 9-cis-RA, which was inhibited by
BI-1003 as well as K-8008 and K-8012 (Figure 2C). Dose-
response experiments showed that the IC50 values for K-8008
and K-8012 to inhibit 9-cis-RA-induced Gal4-RXRa-LBD trans-
activation were about 13.2 and 9.2 mM, respectively (Figure 2D).
Thus, K-8008 and K-8012 are antagonists of RXRa.
K-8008 and K-8012 Induce Apoptosis and Inhibit AKT
Activation by Preventing tRXRa from Binding to p85a
We next evaluated K-8008 and K-8012 for their effect on the
growth of cancer cells. Compared to sulindac, K-8008 and
K-8012 were much more effective in inhibiting the growth of
various cancer cells, including A549 lung cancer (Figure 3A),
PC3prostatecancer, andZR-75-1andMB231breastcancercells
(Figure S1 available online). One unique property of sulindac and
analogs is their ability to inhibit TNF-a-induced AKT activationª2014 Elsevier Ltd All rights reserved 597
Figure 2. Antagonist Effect of Sulindac
Analogs
(A and B) Inhibition of RXRa transactivation.
(TREpal)2-tk-CAT and RXRa were transiently
transfected into CV-1 cells. Cells were treated with
or without 9-cis-RA (107 M) in the presence or
absence of the indicated concentration of sulindac
and its analogs. CAT activity was determined. BI-
1003 (1 mM) was used for comparison. 1, 2, 3, and
4 stand for sulindac, K-80003, K-8008, and
K-8012, respectively.
(C) Inhibition of 9-cis-RA-induced Gal4 reporter
activity. pBind-RXRa-LBD and pG5luc were tran-
siently transfected into HCT-116 cells. Cells were
treated with or without 9-cis-RA (107 M) in the
presence or absence of BI-1003 (1 mM), K-8008
(50 mM), and K-8012 (50 mM). Luciferase (LUC)
activity was determined.
(D) Dose-dependent effect of K-8008 and K-8012.
HCT-116 cells transfected with pBind-RXRa-LBD
and pG5luc were treated with the indicated con-
centrations of K-8008 and K-8012 in the presence
or absence of 9-cis-RA (107 M). All reporter ac-
tivity is expressed as means ± SD from three in-
dependent experiments.
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Sulindac Analogs Bind to an RXRa Site(Zhou et al., 2010). Thus, A549 lung cancer cells were treatedwith
TNF-a in theabsenceorpresenceofK-8008orK-8012.Treatment
of cells with TNF-a enhanced AKT activation as revealed by
western blotting (Figure 3B). However, when cells were cotreated
with either K-8008 or K-8012, the TNF-a-induced AKT activation
was suppressed in a dose-dependentmanner (Figure 3B). Similar
results were obtained in other cancer cell lines (Figure S2).
TNF-a is a multifunctional cytokine that controls diverse
cellular events such as cell survival and death (Balkwill, 2009;
Wang and Lin, 2008). Inhibition of TNF-a-induced AKT activation
by sulindac and analogs in cancer cells led to a shift of TNF-a
signaling from survival to death (Zhou et al., 2010). We therefore
evaluated the effect of K-8008 and K-8012 alone or in combina-
tion with TNF-a on the cleavage of poly(ADP-ribose) polymerase
(PARP), an indication of apoptosis in cancer cells (Lazebnik et al.,
1994). Treatment of A549 cells with TNF-a did not have effect on
PARP cleavage, whereas treatment with sulindac or analogs
slightly induced PARP cleavage. Combination of sulindac or
analogs with TNF-a, however, caused a significant induction of
PARP cleavage (Figure 3C and Figure S3). Thus, K-8008 and
K-8012, like sulindac, could convert TNF-a signaling from sur-
vival to death in cancer cells.
The growth inhibitory effect of K-8008 and K-8012 and the
induction of apoptosis by K-8008 occurred at low micromolar
concentrations, suggesting that they might exert their anticancer
effects through RXRa binding. To address the issues, cancer
cells were transfected with RXRa small interfering RNA (siRNA)
and evaluated for the effect of K-8008 on inducing PARP cleav-
age and inhibiting AKT activation. Knocking down RXRa expres-
sion by RXRa siRNA transfection significantly diminished the
effect of K-8008 on inducing PARP cleavage (Figure 3D) and
inhibiting TNF-a-induced AKT activation (Figure 3E). To address598 Chemistry & Biology 21, 596–607, May 22, 2014 ª2014 Elsevierthe role of tRXRa, RXRa-D80, a RXRamutant lacking its N-termi-
nal 80 amino acids and mimicking tRXRa (Wang et al., 2013;
Zhou et al., 2010), was transfected into HeLa cells. Transfection
of RXRa-D80 but not the full-length RXRa enhanced the effect of
K-8008 on inducing PARP cleavage in the presence of TNF-a
(Figure 3F). Together, these results demonstrate that tRXRa
plays a crucial role in mediating the biological effects of K-8008.
We next determined whether K-8008 could affect tRXRa inter-
action with p85a, an interaction known to activate AKT (Zhou
et al., 2010). HeLa cells were transfected with Myc-tagged
RXRa-D80andFlag-taggedp85aexpression vectors and treated
with or without TNF-a and/or K-8008. Coimmunoprecipitation
assays using anti-Myc antibody showed that Flag-p85a was
coimmunoprecipitated together with Myc-RXRa-D80 in cells
treated with TNF-a (Figure 3G). However, when cells were
cotreated with K-8008, TNF-a-induced interaction of Myc-
RXRa-D80 with Flag-p85a was almost completely inhibited. We
also examined the effect of K-8008 on interaction of endogenous
tRXRa with p85a in A549 cells. Cell lysates prepared from A549
cells treated with TNF-a in the presence or absence of K-8008
were analyzed by coimmunoprecipitation using D197 anti-
RXRa antibody that recognizes both tRXRa and RXRa (Zhou
et al., 2010). Figure 3H shows that treatment of cells with TNF-a
promoted the interaction of endogenous tRXRa with p85a,
consistent with previous findings (Zhou et al., 2010). When cells
were cotreatedwith K-8008, the interactionwas largely inhibited.
Such an effect of K-8008 on inhibiting TNF-a-induced p85a inter-
action with tRXRa was also observed in other cancer cell lines,
including PC3 and HepG2 cells (Figure S4). Together, these re-
sults demonstrate that K-8008 can induce TNF-a-dependent
apoptosis by suppressing the tRXRa-mediated activation of
AKT through its inhibition of tRXRa interaction with p85a.Ltd All rights reserved
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with HepG2 tumor xenografts were treated with 20 mg/kg
K-8008 or K-80003. Administration of K-8008 inhibited the
growth of HepG2 tumor in a time-dependent manner (Fig-
ure 4A), resulting in a 61.23% reduction of tumor weight after
a 12-day treatment (Figures 4B and 4C), which was com-
parable with the inhibitory effect of K-80003 (54.84% reduc-
tion). Consistent with our in vitro observation, examination of
three tumors treated with or without K-8008 showed reduction
of AKT activation by K-8008 (Figure 4D). Moreover, TUNEL
staining revealed induction of apoptosis by K-8008 (Figure 4E).
Significantly, administration of either K-80003 or K-8008 did
not show any apparent toxic effects such as loss of body
weight (Figure 4F).
K-8008 and K-8012 Do Not Bind to the Classical LBP
of RXRa
Although sulindac and analogs can bind tRXRa and induce
tRXRa-dependent apoptosis of cancer cells, how they bind to
tRXRa to regulate tRXRa functions remains undefined. Accord-
ing to current understanding of the mechanism by which
ligands regulate the transcriptional activity of nuclear receptors,
K-8008 and K-8012 might bind to the canonical binding site,
the LBP of RXRa, acting as conventional antagonists. Thus,
we evaluated their binding to the LBP of RXRa using the clas-
sical radioligand competition binding assay (Zhou et al., 2010).
Unlike 9-cis-RA and K-80003 that competed well with [3H]9-
cis-RA for binding to the LBP of RXRa, K-8008 and K-8012
failed to replace [3H]9-cis-RA for its binding to the RXRa LBP
(Figure 5A).
Results of the [3H]9-cis-RA binding competition assay
demonstrated that K-8008 and K-8012 did not bind to the
canonical binding site, suggesting a different binding mecha-
nism. Other than the classical LBP, recent structural and func-
tional studies have revealed the existence of distinct small
molecule binding sites on the surface of the LBD of nuclear re-
ceptors (Buzo´n et al., 2012; Moore et al., 2010). One of the
potential alternative sites in which small molecules could
bind and function as antagonists is the coregulator-binding
site in the LBD. Antagonistic properties displayed by ligands
through binding to the coregulator site have been reported
for several members of the nuclear receptor family. For
example, small molecules mimicking the structure of the coac-
tivator LXXLL a-helical motif have been developed for modu-
lating the activities of AR, ER, and VDR (Mita et al., 2010;
Rodriguez et al., 2004; Arnold et al., 2005; Moore et al.,
2010). We therefore tested whether K-8008 and K-8012 could
bind to an alternative surface binding site by using the time-
resolved fluorescence resonance energy transfer (TR-FRET)
RXRa coactivator peptide competition assay. Our results
showed that both compounds could inhibit 9-cis-RA-induced
interaction of RXRa LBD with its coactivator peptide (Fig-
ure 5B). The inhibitory effect of K-8008 and K-8012 was
much stronger than sulindac, with IC50 values of 16.8 and
14.5 mM, respectively (Figure 5C), which correlated well with
their inhibition of 9-cis-RA-induced RXRa transactivation (Fig-
ure 2D). Taken together, K-8008 and K-8012 might act as
RXRa antagonists by binding to a novel RXRa surface site,
leading to inhibition of coactivator binding.Chemistry & Biology 21,K-8008 andK-8012Bind to a Tetrameric Structure of the
RXRa LBD
To gain direct and structural understanding of the binding of
K-8008 or K-8012 to RXRa, we performed crystallographic
studies of these ligands bound to the RXRa LBD. Crystals of pro-
tein/ligand complexes were obtained using a cocrystallization
method. The structures of RXRa LBD in complex with K-8008
and K-8012 were determined to the resolution of 2.0 and 2.2 A˚,
respectively. Both protein/ligand complexes crystallized as
tetrameric oligomers in the space group of P21 with similar unit
cell parameters, and the molecular replacement method was
used to obtain the initial phasing by using the published RXRa
structure, Protein Data Bank (PDB) code 1G1U. Statistics of
structure refinement and data collection are summarized in
Table S1.
The crystal structure of the RXRa LBD in complex with the
K-8008 exists as noncrystallographic homotetramer similar to
the reported apo homotetramer (Gampe et al., 2000), in which
two homodimers pack in a bottom-to-bottom manner (Figure 6A
and Figure S5A). Superposition of our crystal structure with the
published apo structure (PDB code 1G1U) shows that the corre-
sponding monomers have almost identical folds with small shifts
found in the orientation of H12 in the monomer where a K-8008
molecule is bound (Figure 6B). N-terminal residues, from 223
to 260, were found to be disordered and undetermined in the
complex structures, though residues 231–260 were defined in
the apo structure. In a tetramer, two modulator molecules were
found to bind to one homotetramer, with a binding stoichiometric
ratio of 1:2 between ligand and protein, because one ligand
molecule binds only to one monomer within a dimer (Figure 6A).
Observation of the same stoichiometric ratio between ligand and
protein has been reported for another RXRa-LBD/antagonist
(Gampe et al., 2000). K-8008 binds to a region that is close to
the dimer-dimer interface, making interaction primarily with
one monomer of the dimer and some interaction with one mono-
mer of the other dimer. The structure of RXRa LBD in complex
with K-8012 is very similar to that of RXRa LBD in complex
with K-8008 (Figure S5B). Therefore we describe and discuss
only the protein/K-8008 complex structure here.
Both K-8008 and K-8012 bind to a hydrophobic region of LBD
near the entry and the edge of the cognate LBP. This region does
not overlap with the binding region of 9-cis-RA (Figure 6B), which
explains why both compounds failed to compete with the
binding of 9-cis-RA (Figure 5A). To get a sense of how far
the K-8008 binding region is away from the LBP, we calculated
the distance between the centroid of the bound 9-cis-RA
and the centroid of the bound K-8008 molecule using the tools
available in Maestro. In the superimposed structures of the
K-8008-bound LBD structure with the 9-cis-RA-bound LBD
structure, the two centroids are about 7 A˚ apart (Figure S6A).
The K-8008 hydrophobic binding region is made of side chains
primarily from one monomer: Ala271 and Ala272 from H3;
Trp305 and Leu309 from H5; Leu326 and Leu330 from the
beta-turn; Leu433 from H10; Leu436 from L10-11; Phe437,
Phe438, Ile442, and Gly443 from H11 of chain B2; and Leu436
from L10-11 of chain A1 (Figure 6C). With respect to the mono-
mer of RXRa LBD, this region is located on the surface of the
RXRa monomer molecule. However, in the tetramer structure,
this region is buried. K-8008makes both hydrophobic interaction596–607, May 22, 2014 ª2014 Elsevier Ltd All rights reserved 599
Figure 3. Biological Effects of K-8008 and K-8012
(A) Growth inhibition by sulindac and its analogs. A549 lung cancer cells were treated with various concentrations of the indicated compounds. Cell viability was
measured by the MTT colorimetric assay. The values represent averages (±SD) from five independent experiments. 1, 2, 3, and 4 stand for sulindac, K-80003,
K-8008, and K-8012, respectively.
(B) Inhibition of TNF-a-induced AKT activation. A549 cells were pretreated with sulindac or analogs for 1 hr before being exposed to TNF-a (10 ng/ml) for 30 min.
Phosphorylated AKT and total AKT were analyzed by immunoblotting.
(C) Induction of apoptosis by sulindac and analogs in the presence of TNF-a. Cells cultured in medium with 1% FBS were treated with TNF-a (10 ng/ml) and/or
compound (40 mM) for 4 hr and analyzed for PARP cleavage by immunoblotting.
(D) RXRa siRNA transfection inhibits the apoptotic effect of K-8008. HeLa cells transfected with control or RXRa siRNA for 48 hr were treated with K-8008 (40 mM)
and/or TNF-a (10 ng/ml) for 6 hr and analyzed by immunoblotting.
(E) RXRa siRNA transfection antagonizes the inhibitory effect of K-8008 on AKT activation. HeLa cells transfected with control or RXRa siRNA for 48 hr were
treated with K-8008 (40 mM) for 1.5 hr before being exposed to TNF-a (10 ng/ml) for 30 min and analyzed by immunoblotting.
(F) Myc-RXRa-D80 transfection enhances the apoptotic effect of K-8008. HeLa cells transfected with Myc-RXRa or Myc-RXRa-D80 were treated with K-8008
(20 mM) and/or TNF-a for 12 hr. PARP cleavage and transfected RXRa expression were analyzed by immunoblotting.
(legend continued on next page)
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Figure 4. Inhibition of HepG2 Tumor Growth
in Animals
(A–C) Nude mice with HepG2 heptoma xenografts
were intraperitoneally injected daily with vehicle, K-
8008 (20 mg/kg), or K-80003 (20 mg/kg) for
12 days. Tumors were removed and measured.
Tumor sizes and weights in control and K-80003-
and K-8008-treated mice were compared. In (B),
one of three similar experiments is shown. Error
bars represent SEM.
(D) Lysates prepared from three tumors treated
with vehicle or K-8008 were analyzed by western
blotting assay for p-AKT expression.
(E) H&E staining and TUNEL assay. Tumor sections
were stained for H&E or TUNEL by immunohisto-
chemistry. Increased apoptotic tumor cells were
observed in tumor from K-8008-treated mice.
(F) K-8008 does not exhibit apparent toxicity. Body
weight was measured every 3 days. Each point
represents the mean ± standard deviation of six
mice. The differences between the compound-
treated group and control group are not significant
(p > 5%). One of three similar experiments is
shown. Error bars represent SEM.
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tetrazole of the ligand sits on the top of the N-terminal end of
H11 with a distance of 3 A˚ from the backbone N of residue
Phe438 (Figure S6B), making charge-diploe interaction with
H11 (Figure 6B). At 4.0 A˚ cutoff, the lipophilic part of the ligand
makes van der Waals (VDW) contacts with side chains of
Ile268, Ala271, Trp305, Leu436, Phe438, Phe439, and Ile442
from chain B2 and Leu436 from chain A1 (Figures 6A and 6D).
The overall structure of the K-8008-bound RXRa LBD is identical
to the apo structure of RXRa LBD tetramer. Binding of K-8008
does not induce much significant change in the surrounding
side chains except for the side chains of Phe439 and Leu309.
The side chain of Phe439 swings out to make room for the ligand
to bind, and the side chain of Leu309 rearranges to make better
VDW contact with the ligand (Figure 6E). Compared to the struc-
ture of the RXRa LBD bound to 9-cis-RA (Egea et al., 2000),
K-8008 binding does not result in change in the shape of the
LBP, whereas 9-cis-RA binding induces a substantial change
in the shape of the LBP that includes the movement of H3 and
H11 and the reorientation of H12 (Figure 7A). 9-cis-RA binding
results in the formation of the coactivator-binding site; how-(G) K-8008 inhibits the interaction of transfected tRXRa and p85a. HeLa cells transfected with Myc-RXRa
vehicle or 20 mMK-8008 in the presence of absence of 10 ng/ml TNF-a for 1 hr. Cell lysates were immunopre
by western blotting (WB) analysis using the indicated antibody.
(H) K-8008 inhibits the interaction of endogenous tRXRa and p85a. A549 cells were pretreated with vehicle
10 ng/ml TNF-a for 30 min. Cell lysates were immunoprecipitated with DN197 anti-RXRa antibody and ana
See also Figure S1–S4.
Chemistry & Biology 21, 596–607, May 22, 2014ever, K-8008 binding does not promote
the formation of the coactivator-binding
site. Instead it leaves the receptor protein
in an autorepression state. Thus, K-8008
acts as an antagonist. Similar to 9-cis-
RA ligand, K-8008 is made of largely a
lipophilic body linked to a charged group.The carboxylate group of 9-cis-RA acts as an anchor via forming
charge-charge interaction with Arg316; however, the bioisostere
tetrazole of the carboxylate in K-8008 makes no interaction with
Arg316. The tetrazole group in the RXRa LBD/K-8008 structure
is about 15 A˚ away from Arg316. Both 9-cis-RA and K-8008
make extensive hydrophobic interactions with the protein.
Some of the residues contributing to the hydrophobic interac-
tions between ligand (9-cis-RA or K-8008) and the protein are
shared, such as Ile268, Ala271, and Leu326, but because of
the LBP shape change induced by the binding of 9-cis-RA, these
shared residues are located in different regions of the structures
of RXRa LBD/K-8008 and RXRa LBD/9-cis-RA (Figure S6C).
To further support and cross-validate the identification of this
binding site on RXRa, we designed a couple of mutants that
could potentially impact the binding of K-8008 but not 9-cis-
RA. Comparison of the binding nature of the K-8008 molecule
to that of the 9-cis-RA reveals that Leu433 is close to the tetra-
zole group and that replacing Leu433 with Glu could weaken
the binding of K-8008 because of the repulsive interaction be-
tween the deprotonated Glu and the negatively charged tetra-
zole. However, Leu433Glu is not likely to impact the binding of-D80 and/or Flag-p85a for 24 hr were treated with
cipitated (IP) using anti-Myc antibody and analyzed
or 40 mM K-8008 for 1 hr before being exposed to
lyzed by western blotting.
ª2014 Elsevier Ltd All rights reserved 601
Figure 5. Unique Binding of K-8008 and
K-8012 to RXRa
(A) K-8008 and K-8012 fail to compete with the
binding of 9-cis-RA to RXRa. RXRa-LBD protein
was incubatedwith [3H]9-cis-RA in the presence or
absence of sulindac analogs K-80003, K-8008,
K-8012, or unlabeled 9-cis-RA. Bound [3H]9-cis-
RA was quantitated by liquid scintillation counting.
One of three similar experiments is shown. Error
bars represent SEM. 1, 2, 3, and 4 stand for su-
lindac,K-80003,K-8008, andK-8012, respectively.
(B) K-8008 and K-8012 reduce 9-cis-RA-induced
FRET signal. GST-RXRa-LBD was incubated with
K-8008 or K-8012 in the presence or absence of
9-cis-RA (108 M). BI-1003 (1 mM) was used as a
control. The values represent averages (±SD) from
three independent experiments.
(C) Dose-dependent effect of K-8008 and K-8012
on 9-cis-RA-induced FRET signal. GST-RXRa-
LBD was incubated with K-8008 or K-8012 in the
presence of 9-cis-RA (108 M). The values repre-
sent averages (±SD) from three independent
experiments.
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1FBY); Leu433 is not close to the ligand and is also partially sol-
vent-exposed. This prediction is supported by our reporter
assays showing that 9-cis-RA could similarly activate the wild-
type RXRa (Figure 7B) and the Leu433Glu RXRa mutant,
RXRa-L433E (Figure 7C). By contrast, K-8008 inhibited 9-cis-
RA-induced transactivation of RXRa but not RXRa-L433E.
Structural comparison also suggests that mutating both
Phe438 and Phe439 into Ala could affect the binding of K-8008
but not 9-cis-RA. Indeed, simultaneous substitution of Phe438
and Phe439with Ala resulted in amutant, RXRa-F438,9A, whose
transactivation could be strongly induced by 9-cis-RA, but
K-8008 failed to inhibit the induced transcriptional activity (Fig-
ure 7D). Together, the mutagenesis studies confirm the K-8008
binding site identified by the crystal structure.
DISCUSSION
We report here our identification of two sulindac analogs,
K-8008 and K-8012, which showed potent tRXR inhibitory
effects through a unique binding mechanism. Our results
demonstrated that K-8008 and K-8012 were more effective
than sulindac in inhibiting RXRa transactivation (Figure 2A).
Sulindac binds to RXRa with an IC50 of 82.9 mM based on the
classical ligand competition assays (Zhou et al., 2010). K-8008
and K-8012 could antagonize 9-cis-RA-induced transactivation
and inhibit coactivator peptide binding to RXRa with IC50 value
of around 10 mM. Consistently, K-8008 and K-8012 showed
improved activity than sulindac in inhibiting AKT activation and
inducing apoptosis. About 100 mM of sulindac is normally used602 Chemistry & Biology 21, 596–607, May 22, 2014 ª2014 Elsevier Ltd All rights reservedto achieve its anticancer effects (Weggen
et al., 2001; Yamamoto et al., 1999;
Zhang et al., 2000), whereas 10–50 mM
of K-8008 and K-8012 were able to inhibit
AKT activation and induce apoptosis of
cancer cells. Furthermore, K-8008showed potent inhibitory effect on the growth of tumor cells in
animals without apparent toxicity. Similar to sulindac, inhibition
of AKT activation and induction of apoptosis by K-8008 and K-
8012 were RXRa dependent, likely because of their inhibition
of the interaction between tRXRa and p85a.
K-8008 and K-8012 were synthesized as part of the structure-
activity relationship studies of sulindac, by replacing the carbox-
ylate group in K-80003 with its bioisotere tetrazole (Herr, 2002).
Based on the principle of bioisosteric replacement (Matta
et al., 2010), we anticipated that tetrazole group acted like the
carboxylate group, a commonmotif found inmost of the cognate
RXR ligands, which interacts with Arg316 in the LBP, and there-
fore both K-8008 and K-8012 would compete 9-cis-RA for
binding. To our surprise, both compounds, unlike sulindac and
K-80003, failed to compete with 9-cis-RA for binding to the
LBP, demonstrating that they exert their antagonist effect
through a different binding mechanism from sulindac and
K-80003. Our structure analysis confirmed that the tetrazole
group of K-8008 and K-8012 binds to a region away from
Arg316, and it anchors to the RXRa protein by sitting atop the
N terminus of helix 11, forming the charge-helix dipole interac-
tion. This charge-dipole interaction may also function to stabilize
the orientation and conformation of H11 because in most of the
cases ligand binding to the cognate LBP induces the conforma-
tion change and reorientation of H11(Egea et al., 2000; Sato
et al., 2010). Tetrazole is a nonclassical isotere of –COOHmoiety
(Herr, 2002; Matta et al., 2010). It has a similar PKa to –COOH
but has a different steric characteristics and different number
of atoms from –COOH. Spatially tetrazole moiety is bulkier
than –COOH, and it seems that some spatial clash could prevent
Figure 6. Crystal Structure of the RXRa LBD
in Complex with K-8008
(A) The tetramer structure of RXRa LBD in complex
with K-8008. The two bound K-8008molecules are
shown as magenta sticks surrounded by an elec-
tron density mesh (see Figure 6D legend for
details). The two biological dimers (A1-B1 and A2-
B2) are shown as green/cyan and yellow/brown
pairs, respectively. The N and C termini of four
subunits are marked by the corresponding residue
numbers.
(B) Superposition of the RXRa LBD monomers
from the K-8008-binding structure (brown rib-
bons) and the apo protein structure (purple rib-
bons, from PDB entry 1G1U). K-8008 is shown
as sticks (carbon/nitrogen atoms are in magenta/
blue). The classic ligand binding site is also
marked by a VDW ball model (in cyan/red) of
9-cis-RA taken from a superimposed PDB entry
1FBY.
(C) The hydrophobicity of the K-8008 binding site
presented as a surface fragment on top of the
RXRa LBD monomer (brown ribbon). The hy-
drophobic side chains that contribute to the
region are shown in green, and K-8008 is shown
in the same fashion as in Figure 6B. For clarity,
residues contributing to this region are not
labeled.
(D) The protein side chains (in sticks) that make
VDW interaction with K-8008. The displayed
region is an enlargement of the black box in
Figure 6A. The view is slightly rotated, and
fragments of the green subunit that do not
interact with K-8008 are removed. The protein
surface is shown as semitransparent envelope.
The Fo-Fc electron density is shown around the
ligands as a black mesh. It was calculated at a
3-s level with omitted ligand atoms. The posi-
tive end of the H11 helix dipole is highlighted in
orange.
(E) Side chains around K-8008 that make signifi-
cant changes in comparison with the apo protein
(PDB code 1G1U). Side chains of the apo protein
are shown in green sticks, and the protein/K-8008
complex is shown in orange sticks. The complex
structure is shown in brown ribbon, and the apo
structure is in purple. K-8008 is presented in the
same fashion as in Figure 6B.
See also Figures S5 and S6.
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charge interaction with Arg316. As a result, K-8008 and K-8012
bind to a novel region. The structural results show that the com-
pounds bind to a region that does not overlap with the 9-cis-RA
binding space, offering a structural explanation for the inability of
K-8008 and K-8012 to compete with 9-cis-RA for RXRa binding.
Furthermore, our mutagenesis data (Figures 7B–7D) support the
existence of this K-8008 binding site.
Our crystal structures revealed that K-8008 and K-8012 bind
to a RXRa LBD tetramer structure through a novel hydrophobic
region that is located on the surface of a monomer and near
the dimer-dimer interface in the tetramer. Unlike the binding of
other published ligands, the binding of K-8008 does not change
the shape of the apo RXRa LBP. In addition, K-8008 interactsChemistry & Biology 21,with monomers of each dimer in the tetramer, contributing to
the dimer-dimer interaction. Taken together, K-8008 or K-8012
binding may help to stabilize the tetramer. Stabilizing the tetra-
meric state of RXRa through ligand binding may have important
implications for the regulation of the nongenomic biological
activities of RXRa. Previous studies have demonstrated that
tetramer formation of RXRa serves as a mechanism to suppress
its transactivation (Gampe et al., 2000; Kersten et al., 1998). The
fact that inhibition of tRXRa interaction with p85a by K-8008 and
K-8012 was associated with their binding to the RXRa tetramer
raises an intriguing question that the formation of RXRa homote-
tramer may also represent a mechanism to suppress its interac-
tion with cytoplasmic p85a and activation of tRXRa-dependent
PI3K/AKT signaling.596–607, May 22, 2014 ª2014 Elsevier Ltd All rights reserved 603
Figure 7. Structural Comparison and Muta-
genesis Analysis of the K-8008 Binding Site
(A) Structural superposition of the protein/K-8008
complex and the protein/9-cis-RA complex. The
9-cis-RA-bound structure (PDB code 1FBY) is
in pink cartoon, and 9-cis-RA is in cyan (C atoms)
and red (O atoms) sticks. The K-8008-bound
structure is in light orange cartoon, and K-8008
is in gray (C atoms) and blue (N atoms) sticks.
Side chain Arg316 is displayed for distance
comparison between distances to –COOH and to
tetrazole.
(B–D) Mutational analysis of the K-8008 binding
site. The LBD of RXRa or mutants cloned into
pBind vector and pG5luc were transiently co-
transfected into HCT-116 cells. Cells were
treated with or without 9-cis-RA (107 M) in the
presence or absence of BI-1003 (1 mM) or K-
8008 (50 mM). Luciferase (LUC) activity was
determined.
See also Figure S6. The reporter activity is ex-
pressed as mean ±SD from three independent
experiments.
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the RXRa LBP with high affinity, weak antagonism is commonly
observed for antagonists that target the receptor surface binding
sites (Caboni et al., 2012; Gunther et al., 2008; Hwang et al.,
2009; Rodriguez et al., 2004). Similarly, K-8008 and K-8012
bind to a surface hydrophobic site and display weak antagonist
effects. However, the therapeutic relevance of targeting the
RXRa through this binding site is evidenced by our observation
that both K-8008 and K-8012 could inhibit tRXRa activities in
cancer cells in vitro and tumor growth in animals (Figure 4). In
fact, the existence and therapeutic relevance of the novel sites
other than the LBP have been described for several nuclear
receptors, including estrogen receptor, androgen receptor,
and vitamin D receptor (Caboni et al., 2012; Kojetin et al.,
2008; Mizwicki et al., 2004; Moore et al., 2010; Sun et al.,
2011). Furthermore, in the case of sulindac and analogs, weak
antagonism may be clinically relevant because conventional
administration of sulindac can result in about 10-15 mM sulindac
in the serum of patients (Davies and Watson, 1997; Yamamoto
et al., 1999). Up to approximately 50 mM of sulindac could be
detected in the plasma of humans depending on dose and
schedule (Davies and Watson, 1997), and sulindac can be
concentrated in epithelial cells at concentrations that are at least
20-fold higher than those seen in the serum (Duggan et al., 1980;
Yamamoto et al., 1999). Consistently, we observed that admin-
istration of K-8008 at the dose that effectively inhibited the
growth of tumor cells did not show any apparent toxicity to ani-
mals (Figure 4). Thus, although showing a relatively weak binding
to RXRa, these compounds could be clinically relevant.
SIGNIFICANCE
RXRa represents an intriguing target for pharmacologic
intervention. Unfortunately, the development of RXRa-
based drugs has been hampered by the side effects associ-
ated with targeting its cognate LBP. Thus, discovery of604 Chemistry & Biology 21, 596–607, May 22, 2014 ª2014 Elseviernew strategies for targeting RXRa is significant. We report
here our identification of two sulindac-derived analogs
that exert their anticancer effects by binding to a site of
RXRa, which is different from the classical LBP. These mol-
ecules could serve as chemical probes for studying the role
of tRXRa in cancer. Furthermore, our results provide an
opportunity to specifically target this surface site and thus
may circumvent side effects associated with binding to the
classical RXRa LBP. The development of tRXRa-selective
inhibitors targeting a novel binding site may support a de-
parture from the traditional approach of targeting the LBP
and lead to a new paradigm targeting a functionally impor-
tant surface site, which may lead to more effective and spe-
cific therapeutics.
EXPERIMENTAL PROCEDURES
Compound Synthesis
K-8008 and K-8012 were synthesized using scheme of Figure 1B. See Supple-
mental Information for details.
Cell Culture and Transfection
PC3 prostate cancer, ZR-75-1 breast cancer, and HeLa cervical cancer cells
were grown in RPMI 1640. CV-1 African green monkey kidney, HCT-116 colon
cancer, and A549 lung cancer cells were cultured in DMEM containing 10%
fetal bovine serum. The cells were maintained at 5% CO2 at 37
C. Subconflu-
ent cells with exponential growth were used throughout the experiments. Cell
transfections were carried out by using Lipofectamine 2000 (Invitrogen)
according to the instructions of the manufacturer. Myc-RXRa-r80 and Flag-
p85a expression vectors as well as RXRa siRNA were described (Zhou
et al., 2010). RXRa-L433E and RXRa-F438,9A mutants were constructed by
standard procedure, and their LBDs were cloned into pBind expression vector
(Wang et al., 2013).
CAT Assay
(TREpal)2-tk-CAT (100 ng), b-galactosidase (100 ng), and RXRa (20 ng) were
transiently transfected into CV-1 cells (Zhang et al., 1992). Cells were then
treated with or without 9-cis-RA (107 M) in the presence or absence of
increasing concentrations of compounds for an additional 24 hr. Cells wereLtd All rights reserved
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normalize for transfection efficiency, CAT activities were corrected to b-gal
activities.
Mammalian One Hybrid
HCT-116 cells seeded in 24-well plates were transiently transfected with 50 ng
of pG5luc, 25 ng of pBind-RXRa-LBD, or mutant. Twenty-four hours after
transfection, the medium was replaced by medium containing the sulindac
analogs and/or 9-cis-RA. Cells were washed, lysed, and assayed by using
the Dual-Luciferase Reporter Assay System (Promega). Transfection effi-
ciency was normalized to Renilla luciferase activity.
Protein Expression and Purification
The humanRXRa LBD (residues Thr223 to Thr462)was cloned as anN-terminal
histidine-tagged fusion protein in pET15b expression vector and overproduced
in Escherichia coliBL21 strain. Briefly, cells were harvested and sonicated, and
the extract was incubated with the His60 Ni Superflow resin. The protein-
resin complexes were washed and eluted. The eluent was collected and
concentrated to 5 mg/ml for subsequent trails (Bourguet et al., 1995; Peet
et al., 1998). For crystallization experiment, the His tag was cleaved by
bovine thrombin (Sigma) and removed on the Resource-Q column (GE
Healthcare), using 0.1–1.0 M NaCl gradient and the Tris-Cl buffer (pH 8.0).
The additional purification was done by the gel filtration on a Superdex 200
2660 column (GE Healthcare) pre-equilibrated with the 75 mM NaCl, 20 mM
Tris-Cl buffer (pH 8.0).
Ligand-Binding Competition Assay
The His-tagged human RXRa-LBD(223–462) was incubated in tubes with un-
labeled 9-cis-RA or different concentrations of compounds in 200 ml of binding
buffer (0.15 M KCl, 10 mM Tris,HCl [pH 7.4], 8% glycerol, and 0.5% CHAPS
detergent) at 4C for 1 hr. [3H]9-cis-RA was added to the tubes to final concen-
tration of 7.5 nM and final volume of 300 ml and incubated overnight at 4C. The
RXRa-LBD was captured by nickel-coated beads. Bound [3H]9-cis-RA was
quantitated by liquid scintillation counting.
TR-FRET Retinoic X Receptor a Coactivator Assay
Invitrogen’s LanthsScreen TR-FRET RXRa Coactivator Assay was
conducted according to the manufacturer’s protocol. The TR-FRET ratio
was calculated by dividing the emission signal at 520 nm by the emission
signal at 495 nm.
MTT Assay
Confluent cells cultured in 96-well dishes were treated with various concentra-
tions of compounds for 48 hr. The cells were then incubated with 2 mg/ml
3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide (MTT) for 4 hr
at 37C. MTT solution was then aspirated, and formazan in cells was instantly
dissolved by addition of 150 ml of DMSO eachwell. Absorbancewasmeasured
at 570 nm.
Western Blotting
Cells were lysed, and equal amounts of the lysates were electrophoresed on
10% SDS-PAGE gels and transferred onto polyvinylidene difluoride mem-
branes (Millipore). The membranes were blocked with 5% skimmed milk in
TBST (50 mM Tris-HCl [pH 7.4], 150 mM NaCl, and 0.1% Tween 20) for 1 hr
and then incubated with primary antibodies and secondary antibodies and de-
tected using the ECL system (Thermo). The dilutions of the primary antibodies
were anti-RXRa (rN197; Santa Cruz) in 1:1,000, anti-PARP (H-250; SantaCruz)
in 1:3,000, anti-p85a (Millipore) in 1:1,000, anti-p-AKT (D9E; Cell Signaling
Technology) in 1:1,000, anti-AKT1/2/3 (H-136; Santa Cruz) in 1:1,000, anti-
b-actin (Sigma) in 1:5,000, anti-c-myc (9E10; Santa Cruz), and anti-Flag
(F1804; Sigma).
Coimmunoprecipitation Assay
Cells were harvested and lysed in buffer containing 50 mM HEPES-NaOH
(pH 7.5), 2.5 mM EDTA, 100 mM NaCl, 0.5% NP40, and 10% glycerol, with
1 mM dithiothreitol and proteinase inhibitor cocktail. Immunoprecipitation
was performed as described (Zhou et al., 2010).Chemistry & Biology 21,HepG2 Xenografts
Nude mice (BALB/c, SPF grade, 16–18 g, 4–5 weeks old) were housed
at 28C in a laminar flow under sterilized conditions. Mice were injected sub-
cutaneously with 100 ml of HepG2 cells (2 3 106). For drug treatment, mice
(n = 6) were treated intraperitoneally after 7 days of transplantation with
K-8008 (20 mg/kg), K-80003 (20 mg/kg), or vehicle (Tween 80) once a day.
Body weight and tumor size were measured every 3 days. Mice were
scarified after 12-day drug treatment, and the tumors were removed for
various assessments. All experimentations and animal usage were per-
formed and approved by the Animal Care and Use Committee of Xiamen
University.
Histology and Apoptosis Analysis
Paraffin wax-embedded tumors were cut into 5-mm-thick sections. These
sections were deparaffinized and stained with hematoxylin and eosin (H&E)
according to the standard protocol. Tumor sections of HepG2 xenografts
were also stained with TUNEL for assessing spontaneous apoptosis
according to the manufacturer’s instructions (In situCell Death Detection
Kit; Roche). The images were taken under a fluorescent microscope (Carl
Zeiss).
Crystallization and Structure Solution of the RXR LBD/Ligand
Complexes
The initial crystallization conditions were determined using the sitting-drop
vapor-diffusion method and the crystallization screens Index and PEG-Ion
(Hampton research). Other crystallization chemicals were from Hampton
Research and Sigma. The data were collected from crystals grown in sitting
drops of the 96-well Intelli-Plates (ARI) by the vapor-diffusion method. 0.2 ml
of the protein/ligand complex containing 0.37 mM of RXR LBD, 0.5-0.7 mM
of a ligand, 100 mM NaCl, and 20 mM Tris-Cl buffer (pH 8.0) were mixed
with 0.2 ml of the well solution (20% PEG3330 and 0.2 M magnesium formate
for the K-8008 complex or 0.2 M sodium acetate for the K-8012 complex) and
incubated at 20C. The first crystals appeared in 5–10 days and grew within
same amount of time into 0.2 3 0.2 3 0.05 mm plates. The crystals were
flash-frozen against thewell solution containing 20%PEG400 as a cryoprotec-
tant. The diffraction data were collected from the cryo-cooled crystals (at
100 K) at Beamline BL11-2 of SSRL and processed using the program suites
XDS (Kabsch, 2010) and ccp4i (Collaborative Computational Project, Number
4, 1994).
The structures were solved by the molecular replacement program Phaser
(McCoy et al., 2007) using PDB entry 1G1U as an initial model. The model
rebuilding and refinement were done with Coot (Emsley and Cowtan, 2004)
and the program suite Phenix (Adams et al., 2010). The initial models and
parameter files for the ligands were prepared by eLBOW of Phenix. The data
collection and refinement statistics are presented in Table S1.
Data Analyses
Data are expressed asmeans ± SD from three or more experiments. Statistical
analysis was performed using Student’s t test. Differences were considered
statistically significant with p < 0.05.
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